Al-Abdely, HM, et al. (1999) Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniases. Antimicrobial Agents and Chemotherapy 43, 2910–2914.
Alrajhi, AA, et al. (2002) Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. New England Journal of Medicine 346, 891–895.
Amoils, SP and Heney, C (1999) Acanthamoeba keratitis with live isolates treated with cryosurgery and fluconazole. American Journal of Ophthalmology 127, 718–720.
Andes, D (2013) Optimizing antifungal choice and administration. Current Medical Research and Opinions 29(Suppl. 4), 13–18.
Andriani, G, et al. (2013) Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth. Journal of Medicinal Chemistry 56, 2556–2567.
Aoyama, Y, Yoshida, Y and Sato, R (1984) Yeast cytochrome P-450 catalyzing lanosterol 14 alpha-demethylation. II. Lanosterol metabolism by purified P-450(14)DM and by intact microsomes. Journal of Biological Chemistry 259, 1661–1666.
Aperis, G and Mylonakis, E (2006) Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations. Expert Opinion on Investigational Drugs 15, 579–602.
Apt, W, et al. (1998) Treatment of chronic Chagas’ disease with itraconazole and allopurinol. American Journal of Tropical Medicine and Hygiene 59, 133–138.
Apt, W, et al. (2013) Treatment of Chagas’ disease with itraconazole: electrocardiographic and parasitological conditions after 20 years of follow-up. Journal of Antimicrobial Chemotherapy 68, 2164–2169.
Arnalich-Montiel, F, et al. (2012) Successful monitoring and treatment of intraocular dissemination of acanthamoeba. Archives of Ophthalmology 130, 1474–1475.
Aufderheide, AC, et al. (2004) A 9,000-year record of Chagas’ disease. Proceedings of National Academy of Sciences of the United States of America 101, 2034–2039.
Bang, S, et al. (2010) Treatment with voriconazole in 3 eyes with resistant Acanthamoeba keratitis. American Journal of Ophthalmology 149, 66–69.
Beach, DH, Goad, LJ and Holz, GG (1986) Effects of ketoconazole on sterol biosynthesis by Trypanosoma cruzi epimastigotes. Biochemical and Biophysical Research Communications 136, 851–856.
Beach, DH, Goad, LJ and Holz, GG Jr. (1988) Effects of antimycotic azoles on growth and sterol biosynthesis of Leishmania promastigotes. Molecular and Biochemical Parasitology 31, 149–162.
Benaim, G, et al. (2006) Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole. Journal of Medicinal Chemistry 49, 892–899.
Berman, JD (1997) Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clinical Infectious Diseases 24, 684–703.
Berman, JD, Holz, GG Jr. and Beach, DH (1984) Effects of ketoconazole on growth and sterol biosynthesis of Leishmania mexicana promastigotes in culture. Molecular and Biochemical Parasitology 12, 1–13.
Bern, C, et al. (2011) Trypanosoma cruzi and Chagas’ disease in the United States. Clinical Microbiology Reviews 24, 655–681.
Borelli, D (1987) A clinical trial of itraconazole in the treatment of deep mycoses and leishmaniasis. Reviews of Infectious Diseases 9(Suppl. 1), S57–S63.
Borelli, D, et al. (1979) Ketoconazole, an oral antifungal: laboratory and clinical assessment of imidazole drugs. Postgraduate Medical Journal 55, 657–661.
Brick, KE and Agger, WA (2012) Successful treatment of brainstem blastomycosis with fluconazole. Clinical Medicine and Research 10, 72–74.
Bruggemann, RJ, et al. (2009) Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clinical Infectious Diseases 48, 1441–1458.
Buchkowsky, SS, Partovi, N and Ensom, MH (2005) Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Therapeutic Drug Monitoring 27, 322–333.
Buckner, FS and Urbina, JA (2012) Recent developments in sterol 14-demethylase inhibitors for Chagas disease. International Journal for Parasitology, Drugs and Drug Resistance 2, 236–242.
Buckner, F, et al. (2012) Pharmacological characterization, structural studies, and in vivo activity of anti-Chagas disease lead compounds derived from tipifarnib. Antimicrobial Agents and Chemotherapy 56, 4914–4921.
Calvo, E, et al. (2010) Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole. Antimicrobial Agents and Chemotherapy 54, 919–923.
Campos, R, et al. (1992) Evaluation of the therapeutic activity of fluconazole in acute experimental infection caused by Trypanosoma cruzi. Revista do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo 47, 174–175.
Carbajal, H, et al. (2004) Cyclosporine and low-dose ketoconazole in renal transplant recipients: a single-center experience. Transplantation 77, 1038–1040.
Chapman, SA, et al. (1996) Considerations for using ketoconazole in solid organ transplant recipients receiving cyclosporine immunosuppression. Journal of Transplant Coordination 6, 148–154.
Cherkesova, TS, et al. (2014) Sequence variation in CYP51A from the Y strain of Trypanosoma cruzi alters its sensitivity to inhibition. FEBS Letters 588, 3878–3885.
Clark, NM, Grim, SA and Lynch, JP 3rd (2015) Posaconazole: use in the prophylaxis and treatment of fungal infections. Seminars in Respiratory and Critical Care Medicine 36, 767–785.
Coppens, I and Courtoy, PJ (2000) The adaptative mechanisms of Trypanosoma brucei for sterol homeostasis in its different life-cycle environments. Annual Review of Microbiology 54, 129–156.
Cornely, OA (2017) Isavuconazole: is there a need for a new antifungal? Journal of Antimicrobial Chemotherapy 72, i2–i4.
Dalvie, D, et al. (2002) Biotransformation reactions of five-membered aromatic heterocyclic rings. Chemical Research in Toxicology 15, 269–299.
Daly, K, et al. (2014) Intermediate cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis successfully treated with fluconazole. Clinical and Experimental Dermatology 39, 708–712.
Dauchy, FA, et al. (2016) Trypanosoma brucei CYP51: essentiality and targeting therapy in an experimental model. PLoS Neglected Tropical Diseases 10, e0005125.
Debruyne, D (1997) Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses. Clinical Pharmacokinetics 33, 52–77.
Denning, DW and Bromley, MJ (2015) How to bolster the antifungal pipeline. Science 347, 1414–1416.
Denning, DW, et al. (1989) Treatment of invasive aspergillosis with itraconazole. American Journal of Medicine 86, 791–800.
De Pascale, G and Tumbarello, M (2015) Fungal infections in the ICU: advances in treatment and diagnosis. Current Opinion in Critical Care 21, 421–429.
Docampo, R, et al. (1981) Biochemical and ultrastructural alterations produced by miconazole and econazole in Trypanosoma cruzi. Molecular and Biochemical Parasitology, 3, 169–180.
Dogra, J and Saxena, VN (1996) Itraconazole and leishmaniasis: a randomised double-blind trial in cutaneous disease. International Journal of Parasitology 26, 1413–1415.
Elewa, H, et al. (2015) Therapeutic drug monitoring of voriconazole in the management of invasive fungal infections: a critical review. Clinical Pharmacokinetics 54, 1223–1235.
El-Sayed, NM, et al. (2005) The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease. Science 309, 409–415.
Ezzet, F, et al. (2005) Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clinical Pharmacokinetics 44, 211–220.
Farowski, F, et al. (2010) Intracellular concentrations of posaconazole in different compartments of peripheral blood. Antimicrobial Agents and Chemotherapy 54, 2928–2931.
Felton, T, Troke, PF and Hope, WW (2014) Tissue penetration of antifungal agents. Clinical Microbiology Reviews 27, 68–88.
Filardi, LS and Brener, Z (1987) Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Transactions of the Royal Society of Tropical Medicine and Hygiene 81, 755–759.
Friggeri, L, et al. (2014) Structural basis for rational design of inhibitors targeting Trypanosoma cruzi sterol 14α-demethylase: two regions of the enzyme molecule potentiate its inhibition. Journal of Medicinal Chemistry 57, 6704–6717.
Fromtling, RA (1988) Overview of medically important antifungal azole derivatives. Clinical Microbiology Reviews 1, 187–217.
Frye, LL and Leonard, DA (1999) Lanosterol analogs: dual-action inhibitors of cholesterol biosynthesis. Critical Reviews in Biochemistry and Molecular Biology 34, 123–140.
Gelman, BB, et al. (2001) Amoebic encephalitis due to Sappinia diploidea. Jama 285, 2450–2451.
Goad, LJ, Holz, GG Jr and Beach, DH (1985) Sterols of ketoconazole-inhibited Leishmania mexicana mexicana promastigotes. Molecular and Biochemical Parasitology 15, 257–279.
Goad, LJ, et al. Jr (1989) The activity of ketoconazole and other azoles against Trypanosoma cruzi: biochemistry and chemotherapeutic action in vitro. Molecular and Biochemical Parasitology 32, 179–189.
Graybill, JR and Craven, PC (1983) Antifungal agents used in systemic mycoses. Activity and therapeutic use. Drugs 25, 41–62.
Guedes-da-Silva, FH, et al. (2017) Antitrypanosomal activity of sterol 14alpha-demethylase (CYP51) inhibitors VNI and VFV in the Swiss mouse models of Chagas disease induced by the Trypanosoma cruzi Y strain. Antimicrobial Agents and Chemotherapy 61, pii: e02098-16. doi: 10.1128/aac.02098-16.
Gulin, JEN, et al. (2013) Efficacy of voriconazole in a murine model of acute Trypanosoma cruzi infection. Journal of Antimicrobial Chemotherapy 68, 888–894.
Gullo, A (2009) Invasive fungal infections. Drugs 69, 65–73.
Halim, MA, et al. (1993) Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in a renal transplant recipient after the occurrence of pancreatitis due to stibogluconate. Clinical Infectious Diseases 16, 397–399.
Hardin, TC, et al. (1988) Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrobial Agents and Chemotherapy 32, 1310–1313.
Hargrove, TY, et al. (2011) Substrate preferences and catalytic parameters determined by structural characteristics of sterol 14alpha-demethylase (CYP51) from Leishmania infantum. Journal of Biological Chemistry 286, 26838–26848.
Hargrove, TY, et al. (2012a) CYP51 structures and structure-based development of novel, pathogen-specific inhibitory scaffolds. International Journal of Parasitology. Drugs and Drug Resistance 2, 178–186.
Hargrove, TY, et al. (2012b) Structural complex of sterol 14α-demethylase (CYP51) with 14α-methylenecyclopropyl-Δ7-24, 25-dihydrolanosterol. Journal of Lipid Research 53, 311–320.
Hargrove, TY, et al. (2013) Complexes of Trypanosoma cruzi sterol 14α-demethylase (CYP51) with two pyridine-based drug candidates for Chagas disease: structural basis for pathogen selectivity. Journal of Biological Chemistry 288, 31602–31615.
Hargrove, TY, et al. (2015) Structure-functional characterization of cytochrome P450 sterol 14α-demethylase (CYP51B) from Aspergillus fumigatus and molecular basis for the development of antifungal drugs. Journal of Biological Chemistry 290, 23916–23934.
Hargrove, TY, et al. (2016) Human sterol 14alpha-demethylase as a target for anticancer chemotherapy: towards structure-aided drug design. Journal of Lipid Research 57, 1552–1563.
Hargrove, TY, et al. (2017a) Structural analyses of Candida albicans sterol 14alpha-demethylase complexed with azole drugs address the molecular basis of azole-mediated inhibition of fungal sterol biosynthesis. Journal of Biological Chemistry 292, 6728–6743.
Hargrove, TY, et al. (2017b) Crystal structure of the new investigational drug candidate VT-1598 in complex with Aspergillus fumigatus sterol 14alpha-demethylase provides insights into its broad-spectrum antifungal activity. Antimicrobial Agents and Chemotherapy 61, pii: e00570-17. doi: 10.1128/aac.00570-17.
Haubrich, BA, et al. (2015) Discovery of an ergosterol-signaling factor that regulates Trypanosoma brucei growth. Journal of Lipid Research 56, 331–341.
Heel, RC, et al. (1982) Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs 23, 1–36.
Heeres, J, Meerpoel, L and Lewi, P (2010) Conazoles. Molecules 15, 4129–4188.
Heykants, J, et al. (1990) Pharmacokinetics of oral antifungals and their clinical implications. British Journal of Clinical Practice. Supplement 71, 50–56.
Hirst, LW, et al. (1984) Management of Acanthamoeba keratitis. A case report and review of the literature. Ophthalmology 91, 1105–1111.
Hoekstra, WJ, et al. (2016) Clinical candidate VT-1161's antiparasitic effect in vitro, activity in a murine model of Chagas disease, and structural characterization in complex with the target enzyme CYP51 from Trypanosoma cruzi. Antimicrobial Agents and Chemotherapy 60, 1058–1066.
Horber, FF, et al. (1993) Visceral leishmaniasis after orthotopic liver transplantation: impact of persistent splenomegaly. Transplant International 6, 55–57.
Huang, YC, et al. (1986) Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. Antimicrobial Agents and Chemotherapy 30, 206–210.
Ishibashi, Y, et al. (1990) Oral itraconazole and topical miconazole with debridement for Acanthamoeba keratitis. American Journal of Ophthalmology 109, 121–126.
Ishibashi, H, et al. (2007) Oral administration of itraconazole solution has superior efficacy in experimental oral and oesophageal candidiasis in mice than its intragastric administration. Journal of Antimicrobial Chemotherapy 59, 317–320.
Jennings, TS and Hardin, TC (1993) Treatment of aspergillosis with itraconazole. Annals of Pharmacotherapy 27, 1206–1211.
Jeong, W, et al. (2016) Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience. Journal of Antimicrobial Chemotherapy 71, 3540–3547.
Joice, AC, et al. (2017) Antileishmanial efficacy and pharmacokinetics of DB766-azole combinations. Antimicrobial Agents and Chemotherapy 62, pii: e01129-17. doi: 10.1128/aac.01129-17.
Jolliffe, DS (1986) Cutaneous leishmaniasis from Belize--treatment with ketoconazole. Clinical and Experimental Dermatology 11, 62–68.
Kalb, VF, et al. (1986) Isolation of a cytochrome P-450 structural gene from Saccharomyces cerevisiae. Gene 45, 237–245.
Kauffman, CA, et al. (2007) Posaconazole. Nature Reviews Drug Discovery 6, 183–184.
Keating, GM (2005) Posaconazole. Drugs 65, 1553–1567, discussion 1568-1559.
Konkle, ME, et al. (2009) Indomethacin amides as a novel molecular scaffold for targeting Trypanosoma cruzi sterol 14α-demethylase. Journal of Medicinal Chemistry 52, 2846–2853.
Krieter, P, et al. (2004) Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrobial Agents and Chemotherapy 48, 3543–3551.
Kullberg, BJ and Arendrup, MC (2015) Invasive candidiasis. New England Journal of Medicine 373, 1445–1456.
Lamb, DC, et al. (2015) Azole antifungal agents to treat the human pathogens Acanthamoeba castellanii and Acanthamoeba polyphaga through inhibition of sterol 14alpha-demethylase (CYP51). Antimicrobial Agents and Chemotherapy 59, 4707–4713.
Lass-Flörl, C (2011) Triazole antifungal agents in invasive fungal infections. Drugs 71, 2405–2419.
Lepesheva, GI (2013) Design or screening of drugs for the treatment of Chagas disease: what shows the most promise? Expert Opinion on Drug Discovery 8, 1479–1489.
Lepesheva, GI and Waterman, MR (2004) CYP51--the omnipotent P450. Molecular and Cellular Endocrinology 215, 165–170.
Lepesheva, GI and Waterman, MR (2007) Sterol 14alpha-demethylase cytochrome P450 (CYP51), a P450 in all biological kingdoms. Biochimica et Biophysica Acta 1770, 467–477.
Lepesheva, GI and Waterman, MR (2011) Structural basis for conservation in the CYP51 family. Biochimica et Biophysica Acta 1814, 88–93.
Lepesheva, GI, et al. (2004) CYP51 from Trypanosoma brucei is obtusifoliol-specific. Biochemistry 43, 10789–10799.
Lepesheva, GI, et al. (2006) CYP51 from Trypanosoma cruzi: a phyla-specific residue in the B' helix defines substrate preferences of sterol 14alpha-demethylase. Journal of Biological Chemistry 281, 3577–3585.
Lepesheva, GI, et al. (2007) Sterol 14 alpha-demethylase as a potential target for antitrypanosomal therapy: enzyme inhibition and parasite cell growth. Chemistry Biology 14, 1283–1293.
Lepesheva, G, et al. (2008) CYP51: a major drug target in the cytochrome P450 superfamily. Lipids 43, 1117–1125.
Lepesheva, GI, et al. (2010a) Structural insights into inhibition of sterol 14 alpha-demethylase in the human pathogen Trypanosoma cruzi. Journal of Biological Chemistry 285, 25582–25590.
Lepesheva, GI, et al. (2010b) Crystal structures of Trypanosoma brucei sterol 14 alpha-demethylase and implications for selective treatment of human infections. Journal of Biological Chemistry 285, 1773–1780.
Lepesheva, GI, et al. (2015) VFV as a new effective CYP51 structure-derived drug candidate for Chagas disease and visceral leishmaniasis. Journal of Infectious Diseases 212, 1439–1448.
Leslie, M (2011) Drug developers finally take aim at a neglected disease. Science 333, 933–935.
Li, Y, et al. (2010) Pharmacokinetic/pharmacodynamic profile of posaconazole. Clinical Pharmacokinetics 49, 379–396 310.2165/11319340-000000000-000000000.
Lopez-Barcons, L, et al. (2017) P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models. International Journal of Cancer 141, 405–413.
Louie, A, et al. (1998) Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrobial Agents and Chemotherapy 42, 1105–1109.
Maertens, JA, et al. (2016) Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. The Lancet 387, 760–769.
Martinez-Diaz, RA, et al. (2001) Biological characterization of Trypanosoma cruzi strains. Memorias do Instituto Oswaldo Cruz 96, 53–59.
Mavridou, E, et al. (2010) Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis. Antimicrobial Agents Chemotherapy 54, 4758–4764.
McCabe, RE, Araujo, FG and Remington, JS (1983) Ketoconazole protects against infection with Trypanosoma cruzi in a murine model. American Journal of Tropical Medicine and Hygiene 32, 960–962.
McCabe, RE, Remington, JS and Araujo, FG (1984) Ketoconazole inhibition of intracellular multiplication of Trypanosoma cruzi and protection of mice against lethal infection with the organism. Journal of Infectious Diseases 150, 594–601.
McCabe, RE, Remington, JS and Araujo, FG (1986) In vitro and in vivo effects of itraconazole against Trypanosoma cruzi. American Journal of Tropical Medicine and Hygiene 35, 280–284.
Mellado, E, et al. (2001) Identification of two different 14-alpha sterol demethylase-related genes (cyp51A and cyp51B) in Aspergillus fumigatus and other Aspergillus species. Journal of Clinical Microbiology 39, 2431–2438.
Mitropoulos, K, Gibbons, G and BE, R (1976) Lanosterol 14alpha-demethylase. Similarity of the enzyme system from yeast and rat liver. Steroids 6, 821–829.
Molina, J, et al. (2000) Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrobial Agents and Chemotherapy 44, 150–155.
Molina, I, et al. (2014) Randomized trial of posaconazole and benznidazole for chronic Chagas’ disease. New England Journal of Medicine 370, 1899–1908.
Molina, I, Salvador, F and Sa´nchez-Montalva´, A (2015) The use of posaconazole against Chagas disease. Current Opinion in Infectious Diseases 5, 397–407.
Momeni, AZ, et al. (1996) Treatment of cutaneous leishmaniasis with itraconazole. Randomized double-blind study. Archives of Dermatology 132, 784–786.
Morillo, CA, et al. (2017) Benznidazole and posaconazole in eliminating parasites in asymptomatic T. cruzi carriers: the STOP-CHAGAS trial. Journal of American College of Cardiology 69, 939–947.
Morschhauser, J (2016) The development of fluconazole resistance in Candida albicans – an example of microevolution of a fungal pathogen. Journal of Microbiology 54, 192–201.
Morton, V and Staub, T (2008) A short history of fungicides. doi: 10.1094/APSnetFeature-2008-0308.
Mosca, P, et al. (1985) In vivo and in vitro inhibition of hepatic microsomal drug metabolism by ketoconazole. British Journal of Experimental Pathology 66, 737–742.
Navin, TR, et al. (1992) Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. Journal of Infectious Diseases 165, 528–534.
Nelson, DR (1999) Cytochrome P450 and the individuality of species. Archives of Biochemistry and Biophysics 369, 1–10.
Nelson, DR, et al. (1993) The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA and Cell Biology 12, 1–51.
Nes, WD (2011) Biosynthesis of cholesterol and other sterols. Chemical Reviews 111, 6423–6451.
Nomeir, AA, et al. (2008) Posaconazole (Noxafil, SCH 56592), a new azole antifungal drug, was a discovery based on the isolation and mass spectral characterization of a circulating metabolite of an earlier lead (SCH 51048). Journal of Mass Spectrometry 43, 509–517.
Ohba, M, et al. (1978) Involvement of cytochrome P-450 and a cyanide-sensitive enzyme in different steps of lanosterol demethylation by yeast microsomes. Biochemical and Biophysical Research Communications 85, 21–27.
Oliva, S, et al. (1999) Successful treatment of widely disseminated acanthamoebiasis. Southern Medical Journal 92, 55–57.
Omura, T and Sato, R (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for Its hemoprotein nature. Journal of Biological Chemistry 239, 2370–2378.
Paniz Mondolfi, AE, et al. (2011) Successful treatment of Old world cutaneous leishmaniasis caused by Leishmania infantum with posaconazole. Antimicrobial Agents and Chemotherapy 55, 1774–1776.
Pappas, PG, et al. (2016) Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clinical Infectious Diseases 62, e1–e50.
Pasqualotto, AC, et al. (2010) Voriconazole therapeutic drug monitoring: focus on safety. Expert Opinion on Drug Safety 9, 125–137.
Patel, T and Dhillon, S (2013) Efinaconazole: first global approval. Drugs 73, 1977–1983.
Peng, LW and Lien, YH (2005) Pharmacokinetics of single, oral-dose voriconazole in peritoneal dialysis patients. American Journal of Kidney Disease 45, 162–166.
Perez-Molina, JA and Molina, I (2017) Chagas disease. Lancet 391, 82–94. doi: 10.1016/s0140-6736(17)31612-4.
Perfect, JR, et al. (2010) Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clinical Infectious Diseases 50, 291–322.
Pettit, NN and Carver, PL (2015) Isavuconazole: a new option for the management of invasive fungal infections. Annals of Pharmacotherapy 49, 825–842.
Pinazo, MJ, et al. (2010). Successful treatment with posaconazole of a ratient with chronic Chagas disease and systemic lupus erythematosus. American Journal of Tropical Medicine and Hygiene 82, 583–587.
Pinger, J, Chowdhury, S and Papavasiliou, FN (2017) Variant surface glycoprotein density defines an immune evasion threshold for African trypanosomes undergoing antigenic variation. Nature Communications 8, 828.
Raederstorff, D and Rohmer, M (1985) Sterol biosynthesis de nova via cycloartenol by the soil amoeba Acanthamoeba polyphaga. Biochemical Journal 231, 609–615.
Raederstorff, D and Rohmer, M (1987) Sterol biosynthesis via cycloartenol and other biochemical features related to photosynthetic phyla in the amoeba Naegleria lovaniensis and Naegleria gruberi. European Journal of Biochemistry 164, 427–434.
Raether, W and Seidenath, H (1984) Ketoconazole and other potent antimycotic azoles exhibit pronounced activity against Trypanosoma cruzi, Plasmodium berghei and Entamoeba histolytica in vivo. Zeitschrift Fur Parasitenkunde 70, 135–138.
Rodriguez, MM, et al. (2009) Correlation of In vitro activity,serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. Antimicrobial Agents and Chemotherapy 53, 5022–5025.
Roque, ALR and Jansen, AM (2014) Wild and synanthropic reservoirs of Leishmania species in the Americas. International Journal for Parasitology: Parasites and Wildlife 3, 251–262.
Rybak, JM, et al. (2015) Isavuconazole: pharmacology, pharmacodynamics, and current clinical experience with a new triazole antifungal agent. Pharmacotherapy 35, 1037–1051.
Saenz, RE, Paz, H and Berman, JD (1990) Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis. The American Journal of Medicine 89, 147–155.
Sawyer, PR, et al. (1975 a). Miconazole: a review of its antifungal activity and therapeutic efficacy. Drugs 9, 406–423.
Sawyer, PR, et al. (1975 b) Clotrimazole: a review of its antifungal activity and therapeutic efficacy. Drugs 9, 424–447.
Schell, WA, et al. (2017) Fungal CYP51 inhibitors VT-1161 and VT-1129 exhibit strong in vitro activity against Candida glabrata and C. krusei isolates clinically resistant to azole and echinocandin antifungal compounds. Antimicrobial Agents and Chemotherapy 61, pii: e01817-16. doi: 10.1128/aac.01817-16.
Seijo Martinez, M, et al. (2000) Granulomatous amebic encephalitis in a patient with AIDS: isolation of acanthamoeba sp. Group II from brain tissue and successful treatment with sulfadiazine and fluconazole. Journal of Clinical Microbiology 38, 3892–3895.
Sheehan, DJ, Hitchcock, CA and Sibley, CM (1999) Current and emerging azole antifungal agents. Clinical Microbiology Reviews 12, 40–79.
Sousa, AQ, et al. (2011) High-dose oral fluconazole therapy effective for cutaneous leishmaniasis due to Leishmania (Vianna) braziliensis. Clinical Infectious Diseases 53, 693–695.
Sundar, S, Kumar, K and Singh, VP (1990) Ketoconazole in visceral leishmaniasis. The Lancet 336, 1582–1583.
Superko, HR, Momary, KM and Li, Y (2012) Statins personalized. Medical Clinics of North America 96, 123–139.
Thomson, S, et al. (2017) Characterisation of sterol biosynthesis and validation of 14alpha-demethylase as a drug target in Acanthamoeba. Scientific Reports 7, 8247.
Toubiana, J, et al. (2006) Oral fluconazole treatment for extensive cutaneous leishmaniasis in an 11-year-old child. The Pediatric Infectious Diseases Journal, 25, 1083–1084.
Trabelsi, H, et al. (2012) Pathogenic free-living amoebae: epidemiology and clinical review. Pathologie Biologie (Paris) 60, 399–405.
Trachtenberg, J, Halpern, N and Pont, A (1983) Ketoconazole: a novel and rapid treatment for advanced prostatic cancer. Journal of Urology 130, 152–153.
Trachtenberg, J and Pont, A (1984) Ketoconazole therapy for advanced prostate cancer. Lancet 2, 433–435.
Tracy, M, et al. (2016) Allergic bronchopulmonary aspergillosis. Journal of Fungi 2, 17.
Trzaskos, J, Kawata, S and Gaylor, JL (1986) Microsomal enzymes of cholesterol biosynthesis. Purification of lanosterol 14 alpha-methyl demethylase cytochrome P-450 from hepatic microsomes. Journal of Biological Chemistry 261, 14651–14657.
Tu, EY, Joslin, CE and Shoff, ME (2010) Successful treatment of chronic stromal acanthamoeba keratitis with oral voriconazole monotherapy. Cornea 29, 1066–1068.
Tucker, RM, et al. (1990) Adverse events associated with itraconazole in 189 patients on chronic therapy. Journal of Antimicrobial Chemotherapy 26, 561–566.
Urbina, JA, et al. (1998) Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Antimicrobial Agents and Chemotherapy 42, 1771–1777.
Urcuyo, FG and Zaias, N (1982) Oral ketoconazole in the treatment of leishmaniasis. International Journal of Dermatology 21, 414–416.
Van den Bossche, H, Willemsens, G, Cools, W, Cornelissen, F, Lauwers, WF and van Cutsem, JM (1980) In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis. Antimicrob. Agents Chemother., 17, 922–928. doi: 10.1128/aac.17.6.922.
Vanden Bossche, H (1985) Biochemical targets for antifungal azole derivatives: hypothesis on the mode of action. In McGinnis, MR (ed.). Current Topics in Medical Mycology, vol. 1. New York: Springer-Verlag, pp. 313–351.
Van den Bossche, H (ed.) (1988). Mode of Action of Pyridine, Pyrimidine and Azole Antifungals. Chichester: Ellis Horwood, pp. 79–119.
Van den Bossche, H, et al. (1978) Biochemical effects of miconazole on fungi. II. Inhibition of ergosterol biosynthesis in Candida albicans. Chemico-Biological Interactions 21, 59–78.
Vanden Bossche, H, et al. (1987) Interaction of azole derivatives with cytochrome P-450 isozymes in yeast, fungi, plants and mammalian cells. Pesticide Science 21, 289–306.
Villalta, F, et al. (2013) VNI cures acute and chronic experimental Chagas disease. Journal of Infectious Diseases 208, 504–511.
Walia, R, et al. (2007) A case of successful treatment of cutaneous Acanthamoeba infection in a lung transplant recipient. Transplant Infectious Diseases 9, 51–54.
Walsh, TJ, et al. (2007) Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clinical Infectious Diseases 44, 2–12.
Warn, PA, et al. (2009) Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. Antimicrobial Agents and Chemotherapy 53, 3453–3461.
Webster, D, et al. (2012) Treatment of granulomatous amoebic encephalitis with voriconazole and miltefosine in an immunocompetent soldier. American Journal of Tropical Medicine and Hygiene 87, 715–718.
Wexler, D, et al. (2004) Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. European Journal of Pharmaceutical Sciences 21, 645–653.
White, JM, et al. (2006) Cutaneous leishmaniasis: three children with Leishmania major successfully treated with itraconazole. Pediatric Dermatology 23, 78–80.
Wilby, KJ (2017) A review of the clinical pharmacokinetics and pharmacodynamics of isavuconazole. European Journal of Drug Metabolism and Pharmacokinetics, PMID:29101732. doi: 10.1007/s13318-017-0445-7.
Yeagle, PL, et al. (1977) Differential effects of cholesterol and lanosterol on artificial membranes. Proceedings of the National Academy of Sciences of the United States of America 74, 4924–4926.
Yoshida, Y and Aoyama, Y (1984) Yeast cytochrome P-450 catalyzing lanosterol 14 alpha-demethylation. I. Purification and spectral properties. Journal of Biological Chemistry 259, 1655–1660.
Yoshida, Y and Aoyama, Y (1987) Interaction of azole antifungal agents with cytochrome P-45014DM purified from Saccharomyces cerevisiae microsomes. Biochemical Pharmacology 36, 229–235.
Yoshida, Y, et al. (2000) Sterol 14-demethylase P450 (CYP51) provides a breakthrough for the discussion on the evolution of cytochrome P450 gene superfamily. Biochemical and Biophysical Research Communications 273, 799–804.
Yu, X, et al. (2016) Ligand tunnels in T. brucei and human CYP51: insights for parasite-specific drug design. Biochimica et Biophysica Acta 1860, 67–78.
Zhang, W, et al. (2002) Inhibition of cytochromes P450 by antifungal imidazole derivatives. Drug Metabolism and Disposition 30, 314–318.
Zijlstra, EE, et al. (2003) Post-kala-azar dermal leishmaniasis. Lancet Infectious Diseases 3, 87–98.
Zingales, B, et al. (2009) A new consensus for Trypanosoma cruzi intraspecific nomenclature: second revision meeting recommends TcI to TcVI. Memorias do Instituto Oswaldo Cruz 104, 1051–1054.